Comprehensive medication guide to Neupro including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100/month for approximately 83% of commercially insured patients; Medicare Part D patients most commonly pay $0–$100, with about 32% paying approximately $190/month. Medicaid patients typically pay $4.90–$9.80/month. Prior authorization with step therapy is often required.
Estimated Cash Pricing
$873–$1,095 retail for a 30-patch (30-day) supply at most pharmacies; no generic is available. Eligible commercially insured patients can pay as little as $10/month with the UCB Neupro Patient Savings Card.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Neupro (rotigotine transdermal system) is a once-daily prescription patch that delivers rotigotine — a non-ergoline dopamine agonist — continuously through the skin over 24 hours. It was first approved by the FDA in 2007 and is manufactured by UCB, Inc. As of 2026, Neupro is the only FDA-approved transdermal dopamine agonist patch in the United States.
Neupro is FDA-approved for two conditions: Parkinson's disease (both early-stage as monotherapy and advanced-stage in combination with levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS). The patch bypasses the digestive system entirely, providing stable, continuous drug levels that more closely mimic the brain's natural tonic dopamine signaling compared to oral medications.
Neupro is available in six strengths — 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, and 8 mg per 24 hours — each packaged in cartons of 30 patches (a 30-day supply). There is currently no generic rotigotine patch available in the United States.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Rotigotine is a non-ergoline dopamine agonist that directly stimulates D3, D2, and D1 dopamine receptors in the brain. In Parkinson's disease, the nerve cells that produce dopamine (in the substantia nigra) progressively die, reducing dopamine levels and causing the hallmark motor symptoms. Rather than replacing lost dopamine-producing cells, rotigotine bypasses them entirely — mimicking the dopamine signal by binding directly to the receptors those cells used to activate.
The transdermal patch delivery system dissolves rotigotine from a silicone drug matrix layer through the skin into capillaries, then into the bloodstream, completely bypassing the gastrointestinal tract. This transdermal route reduces nausea compared to oral dopamine agonists and creates a continuous, flat plasma concentration over 24 hours — avoiding the peaks and troughs of oral dosing that contribute to 'on-off' motor fluctuations in Parkinson's patients.
After removing the patch, rotigotine plasma levels decline with a terminal half-life of 5–7 hours. The drug is extensively metabolized by conjugation and N-dealkylation in the liver before elimination. No dose adjustment is required for mild or moderate renal impairment, and dialysis does not meaningfully remove rotigotine from the body.
1 mg/24h — transdermal patch
Starting dose for Restless Legs Syndrome
2 mg/24h — transdermal patch
Starting dose for early-stage Parkinson's disease
3 mg/24h — transdermal patch
Maximum dose for Restless Legs Syndrome
4 mg/24h — transdermal patch
Starting dose for advanced-stage Parkinson's; common maintenance for early PD
6 mg/24h — transdermal patch
Maximum dose for early-stage Parkinson's disease
8 mg/24h — transdermal patch
Maximum dose for advanced-stage Parkinson's disease
Neupro is not on the FDA's official drug shortage list as of 2026, but many patients experience real difficulty finding it at local pharmacies. The challenges stem from its brand-only status (no generic available), its high wholesale cost ($873–$1,095 per 30-patch supply), and the fact that it comes in six separate dosing strengths — each a distinct SKU that pharmacies must individually stock. Smaller and independent pharmacies may carry only one or two strengths, or none at all.
Higher doses (6 mg/24h and 8 mg/24h) used for advanced Parkinson's disease are particularly prone to local stockouts. Large chain pharmacies (CVS, Walgreens) and mail-order specialty pharmacies generally have more reliable Neupro availability than small community pharmacies. Prior authorization requirements from insurance can create additional access delays even when stock is available.
If you are having trouble locating Neupro, medfinder calls pharmacies near you to find which ones have your specific Neupro strength in stock, then texts you the results — saving you hours of phone calls.
Neupro (rotigotine) is not a DEA-controlled substance, so any licensed prescriber with standard prescribing authority can write a Neupro prescription — no special DEA registration or waiver is required. Prescriptions can be electronic, written, or phoned in.
Types of clinicians who commonly prescribe Neupro include:
Neupro can also be prescribed via telehealth in most states, since it is not a controlled substance. Telehealth platforms like Teladoc, MDLive, and neurology-specific telehealth services can manage Neupro therapy remotely — particularly helpful for Parkinson's patients with limited mobility or those living in areas with limited specialist access.
No. Neupro (rotigotine) is not a DEA-scheduled controlled substance. It has no abuse potential recognized by the DEA, and animal studies and clinical trials with rotigotine have not revealed any potential for drug-seeking behavior or physical dependence in the traditional sense.
Because Neupro is not a controlled substance, any licensed prescriber — including physicians, nurse practitioners, and physician assistants with prescribing authority — can write a prescription without special DEA registration requirements. Prescriptions can be called in, faxed, or e-prescribed like any non-controlled medication. There are no quantity limits imposed by the DEA, and refills are permitted under standard prescription rules.
Note that while Neupro is not federally controlled, insurance plans may apply their own quantity limits or prior authorization requirements before covering the prescription. Abrupt discontinuation of Neupro — while not a controlled substance withdrawal — can cause dopamine agonist withdrawal syndrome, a medically significant condition. Always taper under a doctor's supervision.
The following side effects occur in more than 5% of Neupro patients in clinical trials:
Know what you need? Skip the search.
Pramipexole (Mirapex ER)
Non-ergoline dopamine agonist (D2/D3), once-daily oral tablet, generic widely available, approved for PD and RLS. Closest pharmacological match to rotigotine.
Ropinirole (generic)
Non-ergoline dopamine agonist, oral tablet (immediate-release 3x/day or XL once-daily for PD), generic widely available at low cost. XL formulation approved for PD only; IR approved for PD and RLS.
Carbidopa/Levodopa (Sinemet)
Gold standard for Parkinson's disease motor symptoms; dopamine precursor rather than receptor agonist. Generic widely available, inexpensive. Not approved for RLS.
Gabapentin enacarbil (Horizant)
Non-dopaminergic option for RLS only (not Parkinson's); FDA-approved for moderate-to-severe RLS; no augmentation risk; 2025 AASM guidelines favor as first-line for RLS long-term therapy.
Prefer Neupro? We can find it.
Antipsychotics (haloperidol, risperidone, amisulpride, etc.)
majorDopamine antagonists directly oppose rotigotine's mechanism; may worsen Parkinson's symptoms. Contraindicated with amisulpride; use caution with all antipsychotics.
Metoclopramide (Reglan)
majorDopamine antagonist antiemetic; blocks the receptors Neupro activates. Avoid combination; use dopamine-neutral antiemetics (e.g., ondansetron) instead.
Sodium oxybate (Xyrem/Lumryz)
majorProfound CNS and respiratory depression risk when combined. Avoid combination.
CNS depressants (opioids, benzodiazepines, sleep aids, alcohol)
moderateAdditive sedation and psychomotor impairment; increases risk of sudden sleep onset and falls. Use with caution; avoid alcohol.
Antihypertensive medications
moderateEnhanced orthostatic hypotension; increased risk of dizziness and fainting when standing. Monitor blood pressure when initiating or adjusting doses.
Levodopa (carbidopa/levodopa)
moderateIntended combination for advanced PD; may increase dyskinesia. Monitor for involuntary movements and adjust levodopa dose as needed.
Neupro (rotigotine) is a clinically valuable medication that offers something no oral dopamine agonist can match: 24-hour continuous transdermal delivery that closely mirrors the brain's natural tonic dopamine signaling. For Parkinson's patients with motor fluctuations or difficulty swallowing, and for RLS patients who need round-the-clock coverage, the patch format is a genuine therapeutic advantage. Its non-ergoline profile avoids the cardiac fibrosis risks of older dopamine agonists, and its FDA approval for both early and advanced Parkinson's disease makes it useful across the disease continuum.
The main challenges are cost and access. At approximately $806–$1,095 per month at retail, Neupro is expensive — but multiple programs exist to significantly reduce what most patients pay. The UCB savings card can bring copays to $10/month for commercially insured patients, and Medicare and Medicaid patients have separate assistance pathways. Localized pharmacy availability is inconsistent due to brand-only status and six-SKU fragmentation, but this is a solvable logistical problem rather than a clinical one.
If you have been prescribed Neupro and are struggling to find it in stock, medfinder can locate pharmacies near you that currently have your specific Neupro strength ready to fill — without requiring you to make a single phone call.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini